CL2021000430A1 - Inhibidores de arginasa y sus métodos de uso - Google Patents
Inhibidores de arginasa y sus métodos de usoInfo
- Publication number
- CL2021000430A1 CL2021000430A1 CL2021000430A CL2021000430A CL2021000430A1 CL 2021000430 A1 CL2021000430 A1 CL 2021000430A1 CL 2021000430 A CL2021000430 A CL 2021000430A CL 2021000430 A CL2021000430 A CL 2021000430A CL 2021000430 A1 CL2021000430 A1 CL 2021000430A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- arginase inhibitors
- boraspiro
- dodecan
- aza
- Prior art date
Links
- 102000004452 Arginase Human genes 0.000 title 1
- 108700024123 Arginases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- MVHFGAWLHMAREF-IIYDPXPESA-N (3R,5R)-3-[(4S)-2,2-dimethyl-5-oxo-4-propan-2-ylimidazolidin-1-yl]-10-hydroxy-11-oxa-1-aza-10-boraspiro[4.7]dodecan-12-one Chemical compound OB1OC([C@]2(C[C@H](CN2)N2C(N[C@H](C2=O)C(C)C)(C)C)CCCC1)=O MVHFGAWLHMAREF-IIYDPXPESA-N 0.000 abstract 1
- XUXJHBAJZQREDB-UHFFFAOYSA-N 2-methylbutanamide Chemical compound CCC(C)C(N)=O XUXJHBAJZQREDB-UHFFFAOYSA-N 0.000 abstract 1
- -1 dodecan-3-yl Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721113P | 2018-08-22 | 2018-08-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021000430A1 true CL2021000430A1 (es) | 2021-09-03 |
Family
ID=67742403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021000430A CL2021000430A1 (es) | 2018-08-22 | 2021-02-19 | Inhibidores de arginasa y sus métodos de uso |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11952392B2 (https=) |
| EP (2) | EP4371614A3 (https=) |
| JP (1) | JP7441210B2 (https=) |
| KR (1) | KR102668252B1 (https=) |
| CN (1) | CN112584900B (https=) |
| AU (1) | AU2019323663B2 (https=) |
| CA (1) | CA3109100A1 (https=) |
| CL (1) | CL2021000430A1 (https=) |
| DK (1) | DK3840837T3 (https=) |
| EA (1) | EA202190532A1 (https=) |
| ES (1) | ES2980252T3 (https=) |
| FI (1) | FI3840837T3 (https=) |
| HR (1) | HRP20240694T1 (https=) |
| HU (1) | HUE066903T2 (https=) |
| IL (1) | IL280924B2 (https=) |
| LT (1) | LT3840837T (https=) |
| MA (1) | MA53427B1 (https=) |
| MX (1) | MX2021002042A (https=) |
| PL (1) | PL3840837T3 (https=) |
| PT (1) | PT3840837T (https=) |
| RS (1) | RS65608B1 (https=) |
| SG (1) | SG11202101618PA (https=) |
| SI (1) | SI3840837T1 (https=) |
| SM (1) | SMT202400221T1 (https=) |
| WO (1) | WO2020038983A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI877770B (zh) | 2018-02-27 | 2025-03-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶 |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| WO2020010197A1 (en) | 2018-07-05 | 2020-01-09 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| PH12021551902A1 (en) * | 2019-02-08 | 2022-08-01 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201503168VA (en) * | 2010-04-22 | 2015-06-29 | Mars Inc | Inhibitors of arginase and their therapeutic applications |
| US10143699B2 (en) * | 2015-06-23 | 2018-12-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| JP2020502259A (ja) * | 2016-11-08 | 2020-01-23 | カリセラ バイオサイエンシズ，インコーポレイテッド | アルギナーゼ阻害剤併用療法 |
| CN114989205A (zh) | 2016-12-22 | 2022-09-02 | 卡里塞拉生物科学股份公司 | 用于抑制精氨酸酶活性的组合物和方法 |
| CN117186134A (zh) | 2018-02-17 | 2023-12-08 | 阿斯利康(瑞典)有限公司 | 精氨酸酶抑制剂及其使用方法 |
| EP3765006A4 (en) | 2018-03-13 | 2022-02-23 | Merck Sharp & Dohme Corp. | ARGINASE INHIBITORS AND METHODS OF USE |
| CN111770756B (zh) | 2018-04-27 | 2023-03-31 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途 |
-
2019
- 2019-08-21 MA MA53427A patent/MA53427B1/fr unknown
- 2019-08-21 KR KR1020217007915A patent/KR102668252B1/ko active Active
- 2019-08-21 SI SI201930758T patent/SI3840837T1/sl unknown
- 2019-08-21 CN CN201980055111.3A patent/CN112584900B/zh active Active
- 2019-08-21 SM SM20240221T patent/SMT202400221T1/it unknown
- 2019-08-21 HR HRP20240694TT patent/HRP20240694T1/hr unknown
- 2019-08-21 EP EP24162089.7A patent/EP4371614A3/en active Pending
- 2019-08-21 SG SG11202101618PA patent/SG11202101618PA/en unknown
- 2019-08-21 FI FIEP19758683.7T patent/FI3840837T3/fi active
- 2019-08-21 AU AU2019323663A patent/AU2019323663B2/en active Active
- 2019-08-21 US US17/269,569 patent/US11952392B2/en active Active
- 2019-08-21 RS RS20240642A patent/RS65608B1/sr unknown
- 2019-08-21 IL IL280924A patent/IL280924B2/en unknown
- 2019-08-21 EP EP19758683.7A patent/EP3840837B1/en active Active
- 2019-08-21 LT LTEPPCT/EP2019/072341T patent/LT3840837T/lt unknown
- 2019-08-21 HU HUE19758683A patent/HUE066903T2/hu unknown
- 2019-08-21 MX MX2021002042A patent/MX2021002042A/es unknown
- 2019-08-21 JP JP2021509794A patent/JP7441210B2/ja active Active
- 2019-08-21 DK DK19758683.7T patent/DK3840837T3/da active
- 2019-08-21 PT PT197586837T patent/PT3840837T/pt unknown
- 2019-08-21 ES ES19758683T patent/ES2980252T3/es active Active
- 2019-08-21 EA EA202190532A patent/EA202190532A1/ru unknown
- 2019-08-21 WO PCT/EP2019/072341 patent/WO2020038983A1/en not_active Ceased
- 2019-08-21 CA CA3109100A patent/CA3109100A1/en active Pending
- 2019-08-21 PL PL19758683.7T patent/PL3840837T3/pl unknown
-
2021
- 2021-02-19 CL CL2021000430A patent/CL2021000430A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000430A1 (es) | Inhibidores de arginasa y sus métodos de uso | |
| ECSP20025899A (es) | Compuestos útiles para inhibir a cdk7 | |
| CY1124789T1 (el) | Πυριμιδιν-2-υλαμινο-1η-πυραζολια ως αναστολεις lrrk2 για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων | |
| JOP20220130A1 (ar) | مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم | |
| MX2022001421A (es) | Compuesto tetracíclico, método de preparación y uso del mismo. | |
| ECSP22018571A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| MX2023008453A (es) | Metodos de tratamiento para el abuso de sustancias. | |
| MX2020013116A (es) | Sales y cristales novedosos. | |
| BR112022009563A2 (pt) | Compostos de pirrolotriazina atuando como inibidor de mnk | |
| CR20190124A (es) | Inhibidores de ssao de aminopirimidina | |
| BR112020012712A8 (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos do referido composto para o tratamento de distúrbios do snc | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| MX2020007271A (es) | Sales y cristales novedosos. | |
| MA53973A (fr) | Inhibiteurs de la réplication du virus de l'immunodéficience humaine | |
| UY35781A (es) | Inhibidores de kras g12c. | |
| BRPI0514372A (pt) | inibidores de tiazol de frutose 1, 6-bisfosfatase | |
| BR112021022536A2 (pt) | Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo | |
| AR117920A1 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| MX394624B (es) | Inhibidores selectivos hdac6, métodos de preparación y aplicación de los mismos. | |
| CL2019001694A1 (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos. | |
| BR112017028456A2 (pt) | composto, e, método de prevenção e/ou tratamento de hiv | |
| CL2019001804A1 (es) | Activador de nrf2. | |
| MX2022003585A (es) | Metodos para tratar hiperfenilalaninemia. | |
| CO2017008115A2 (es) | Ácido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico | |
| MX2024008671A (es) | Metodos de tratamiento de infecciones micobacterianas usando compuestos de tetraciclina. |